HAPLN3 and benign prostatic hyperplasia: The three‐gene panel ST6GALNAC3/CCDC181/HAPLN3 was the best performing minimal multimarker panel in our patient set, showing 67% sensitivity and 100% specificity for patients with PC compared to patients with BPH and a corresponding AUC of 0.833 in ROC curve analysis (Fig. 3A (red box), Fig. 3C, and Table S6), thus clearly improving sensitivity over the best performing single marker (HAPLN3).